The plasma phosphorylated tau 217 is proposed to distinguish AD from non-AD neurodegenerative individuals, since its level increases more steeply in non-demented individuals with amyloid positivity than those without amyloid positivity [13]. This evidence concerns the gene MAPT and Alzheimer disease.